Healthy
Conditions
Keywords
Pharmacokinetic, No interaction, Fixed-dose combination (FDC), Ibuprofen, Acetaminophen, Pain
Brief summary
This study was carried out in the Clinical and Analytical Unit of the Pharmacology and Toxicology Department of the Faculty of Medicine of the Autonomous University of Nuevo León, with the aim of comparing the bioavailability (Cmax, AUC) of an oral formulation containing ibuprofen 400 mg/ Acetaminophen 1000 mg in combination with the two oral formulations ibuprofen 400 mg or Acetaminophen 1000 mg administered as a single dose, in healthy subjects under fasting conditions
Detailed description
The study design was crossover, 3 x 6 x 3, open, prospective and longitudinal, at a single dose of the combination of Ibuprofen 200mg/ Acetaminophen 500mg (2 tablets), administered orally versus each component administered individually Ibuprofen 400mg (1 tablet) or Acetaminophen 500 mg (2 tablets), with three treatments, three periods, six sequences with an elimination period (washout) of 1 week and with a number of 42 healthy subjects, of both genders, under fasting conditions. In order to compare the pharmacokinetic profile (Cmax and AUC 0-t) of the combination Ibuporfen/Acetaminophen 200 mg / 500 mg, single dose versus each component administered individually, to establish the non-interaction of the drugs in combination. Like, Characterize the pharmacokinetic parameters, Cmax and AUC 0-t, AUC 0-, Tmax, Ke and T1/2, of Ibuprofen and Acetaminophen after oral administration in a single dose. The frequency and type of adverse events with the two formulations were established.
Interventions
DRUGA1: Ibuprofen/Acetaminophen Fixed dose combination (Laboratorios Silanes S.A. de C.V.)
Formula : 200 mg/ 500 mg Pharmaceutical Form: Tablet Dosage: 400 mg / 1000 mg (2 tablets) Administration way: oral
DRUGA2: Ibuprofen (Motrin®, Pfizer S.A. de C.V.)
A2: Pharmaceutical Form: tablet Dosage: 400 mg (1 tablet) Administration way: oral
DRUGA3: Acetaminophen (Tylenol caplets®, from Janssen-Cilag, S.A. de C.V.)
A3:Pharmaceutical Form: tablet Formula: Acetaminophen 500 mg Dosage: 1000 mg (2 tablets) Administration way: oral
Sponsors
Laboratorios Silanes S.A. de C.V.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* The subjects must have been accepted by the COFEPRIS research subjects registration database. * Subjects without a subordinate relationship with the researchers. * Subjects who have given informed consent in writing. * Subjects of both genders, aged between 18 and 55 years, Mexicans. * Subjects with no background of hypersensitivity or allergies to the drug under study or related drugs. * Body mass index between 18 and 27 kg/m2. * Healthy subjects, according to the results of the complete clinical history, electrocardiogram and the integration of the results of the clinical analyses, carried out in certified clinical laboratories, without alterations that require a medical intervention as a consequence. * Subjects with negative results for immunological tests (Anti-HIV, Anti-hepatitis B and C, VDRL). * Subjects with negative results in drug abuse screening tests: tetrahydrocannabinoids, cocaine and amphetamines. * Negative (qualitative) pregnancy test for women of childbearing potential without Bilateral tubal obstruction or hysterectomy. * In the case of women of childbearing age, they must have a birth control method, including barrier methods, non-hormonal intrauterine device, or bilateral tubal obstruction.
Exclusion criteria
* Subjects with recent history or physical examination evidence of gastrointestinal, renal, hepatic, endocrine, respiratory, cardiovascular, dermatological, or hematological disease that could affect the pharmacokinetic study of the product in research. * Subjects who have been exposed to drugs known as liver enzyme inducers or inhibitors or who have taken drugs potentially toxic within 30 days before the start of the study. * Subjects who have received any medication during the 7 days before the start of the study. * Subjects who have been hospitalized for any problem during the three months before the start of the study. * Subjects who have been rejected by the registry database of research subjects of COFEPRIS, for having participated in a clinical study within the three months prior to the start of the study. * Subjects who have received investigational drugs within the previous 60 days th the start of the study. * Subjects allergic to the study drug or related drugs. * Subjects who have ingested alcohol or drinks containing xanthines (coffee, tea, cocoa, chocolate, cola) or who have eaten charcoal-grilled food or grapefruit juice , at least 10 hours before the start of the study or who have smoked tobacco 24 hours before to the start of the internment period. * Subjects who have donated or lost 450 mL or more of blood within the previous 60 days of the beginning of the study. * Subjects with a history of drug and/or alcohol abuse according to the DSM-IV-TR Criteria. * Research subjects who presents alterations in the vital signs recorded during the selection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum observed concentration following the treatment (Cmax), | Baseline, 0.16, 0.33, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0, 12,0 and 14.0 hours | Evaluate the pharmacokinetics profile of the fixed dose Ibuprofen/Acetaminophen, employing the maximum observed concentration following the treatment (Cmax), obtained graphically, from the plasma concentration profile with respect to time. |
| The area under the curve from time zero to the last measurable concentration (AUC 0-t) | Baseline, 0.16, 0.33, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0, 12,0 and 14.0 hours | Evaluate the fixed dose pharmacokinetics profile of Ibuprofen/Acetaminophen, employing the area under the curve from time zero to the last measurable concentration (AUC 0-t) using the linear trapezoidal method. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Elimination rate (Ke) | Baseline, 0.16, 0.33, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0, 12,0 and 14.0 hours | Evaluate the fixed dose pharmacokinetics profile of Ibuprofen/Acetaminophen, employing the elimination rate (Ke), estimated from the terminal linear portion of the plasma concentration profile with respect to time (on a semi-log scale) |
| Half time elimination (t1/2) | Baseline, 0.16, 0.33, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0, 12,0 and 14.0 hours | Evaluate the pharmacokinetics profile of the fixed dose Ibuprofen/Acetaminophen, employing the half time elimination (t1/2) by the quotient of Ln(2)Ke. |
| The area under the curve from time zero to infinity calculated (AUC 0-inf) | Baseline, 0.16, 0.33, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0, 12,0 and 14.0 hours | Evaluate the fixed dose pharmacokinetics profile of Ibuprofen/Acetaminophen, employing the area under the curve from time zero to infinity calculated (AUC 0-inf). |
| Adverse Events | 1, 8 and 16 days | Any adverse event were classified by severity, treatment and its relationship with the study drug was evaluated. |
| Frequency of occurrence of adverse events | 1, 8 and 16 days | The percentage of frequency of appearance of each adverse event was evaluated. |
| Time of the maximum measured concentration (Tmax) | Baseline, 0.16, 0.33, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0, 12,0 and 14.0 hours | Evaluate the fixed dose pharmacokinetics profile of Ibuprofen/Acetaminophen employing time of the maximum measured concentration Tmax), Obtained graphically, from the plasma concentration profile with respect to time. |
Countries
Mexico
Outcome results
None listed